You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康華生物(300841.SZ)擬4125萬元增資入股可恩生物
格隆匯 03-01 20:40

格隆匯 3 月 1日丨康華生物(300841.SZ)公佈,公司與杭州泰格股權投資合夥企業(有限合夥)(“杭州泰格”)、成都可恩生物科技有限公司(“可恩生物”或“標的公司”)及其股東於近日簽署了《關於成都可恩生物科技有限公司之股權轉讓及增資協議》,公司與杭州泰格擬共同投資入股可恩生物,增資價格一致,其中公司以自有資金人民幣4125.00萬元以增資方式入股可恩生物,對應增資後10%的可恩生物股權。

可恩生物成立於2018年3月7日,主要專注於結核病診斷及膀胱癌治療生物製品的研發、生產及銷售,在研產品包括卡介菌純蛋白衍生物(BCG-PPD)、治療用卡介苗、結核菌素純蛋白衍化物(TB-PPD)、重組結核桿菌融合蛋白(EEC)、NTM等,其中NTM為可恩生物的首創產品,目前可恩生物尚未實現產品上市銷售,在研產品卡介菌純蛋白衍生物(BCG-PPD)處於申報臨牀階段,其餘項目均處於申報臨牀前的研究階段。

此次增資完成後,公司持有標的公司10.00%股權,並將以唯一且獨佔許可的方式取得標的公司治療用卡介苗的中國大陸地區推廣權,有利於公司繼續優化業務結構、增加盈利來源,也有利於推進結核病診斷與膀胱癌防治事業的發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account